Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
1.
J Stroke Cerebrovasc Dis ; 28(2): 425-429, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30396837

ABSTRACT

BACKGROUND: Imaging modalities are important part of stroke evaluation. Noncontrast head computed tomography (CT) is the initial imaging modality in acute stroke and although important to rule out acute hemorrhage and making a decision on thrombolytic treatment, ischemic changes may not be visible on CT for up to 24 hours. Magnetic resonance imaging (MRI) brain is an invaluable tool to confirm an ischemic stroke and facilitates stroke evaluation. Objective of this study was to investigate the correlation between time to MRI and length of hospital stay. METHODS: A total of 432 patients admitted to Hartford Hospital (Comprehensive Stroke Center) with a focal neurological deficit in the year 2014 and got a CT head and MRI brain were enrolled in the study. Data collection was done via stroke database and retrospective chart review. Patients with any hemorrhage or age <18 years were excluded from the study. Patients were categorized as having had an early (within 12 hours) or a late (more than 12 hours) MRI. We used chi-square and Wilcoxon ranked sum test to compare time from arrival to MRI and length of stay in the hospital. RESULTS: There was a statistically significant difference in hospital length of stay between patients who obtained MRI within 12 hours, as compared with patients who had MRI greater than 12 hours after admission, early MRI group 3 days (1.8, 4.9) versus 4 days (2.6, 7.0), P < .001. CONCLUSIONS: Our study suggests that brain MRI performed within 12 hours of admission facilitates stroke evaluation and decreases hospital length of stay. It provides evidence for cost effectiveness of MRI in ischemic stroke.


Subject(s)
Brain Ischemia/diagnostic imaging , Length of Stay , Magnetic Resonance Imaging , Stroke/diagnostic imaging , Aged , Brain Ischemia/therapy , Connecticut , Female , Humans , Male , Patient Admission , Patient Discharge , Predictive Value of Tests , Retrospective Studies , Stroke/therapy , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
2.
Birth Defects Res A Clin Mol Teratol ; 82(9): 622-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18655127

ABSTRACT

BACKGROUND: In 1998, fortification of a large variety of cereal products with folic acid became mandatory in Canada. A multicentric study was carried out to assess the impact of this policy on the frequency of NTDs. The present analysis focused on spina bifida. METHODS: The study population included approximately 2 million livebirths, stillbirths, and terminations of pregnancies because of fetal anomalies among women residing in seven Canadian provinces, from 1993 to 2002. Spina bifida cases were divided according to the upper limit of the defect: upper (cranial, cervical, or thoracic) and lower (lumbar or sacral) defects. Based on published results of red blood cell folate tests, the study period was divided into prefortification, partial fortification, and full fortification periods. RESULTS: A total of 1,286 spina bifida cases were identified: 51% livebirths, 3% stillbirths, and 46% terminations. Prevalence decreased from 0.86/1,000 in the prefortification to 0.40 in the full fortification period, while the proportion of upper defects decreased from 32% to 13%. Following fortification, regional variations in the prevalence and distribution of sites almost disappeared. CONCLUSIONS: Results confirmed the etiologic heterogeneity of spina bifida and the more pronounced effect of folic acid in decreasing the risk of the more severe clinical presentations.


Subject(s)
Folic Acid/administration & dosage , Folic Acid/physiology , Food, Fortified , Spinal Dysraphism/epidemiology , Canada/epidemiology , Female , Humans , Male , Pregnancy , Prevalence , Retrospective Studies , Spinal Dysraphism/metabolism , Spinal Dysraphism/prevention & control
3.
Birth Defects Res A Clin Mol Teratol ; 82(2): 106-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18050337

ABSTRACT

BACKGROUND: Recent studies reported no reduction in the frequency of lipomeningomyelocele (LMMC) in Hawaii and Nova Scotia after the implementation of a folic acid food fortification policy in 1998, while a marked reduction in the prevalence of other NTDs was observed. This study was performed to assess the prevalence of LMMC in Canada in relation to the timing of food fortification. METHODS: The study population included livebirths, stillbirths, and terminations of pregnancies because of fetal anomaly to women residing in seven Canadian provinces, from 1993 to 2002. In each province, the ascertainment of NTD cases relied on multiple sources, and in addition all medical charts were reviewed. The study period was divided into pre-, partial, and full fortification periods, based on results of red cell folate tests published in the literature. RESULTS: A total of 86 LMMC cases were recorded among approximately 1.9 million live births. The average birth prevalence rate was 0.05/1,000, ranging from a minimum of 0.01/1,000 in 2002 to a maximum of 0.08/1,000 in 1999. There was statistical heterogeneity between years (p = .01), but no pattern compatible with a decrease following fortification. Comparing the full fortification period with the prefortification period, there was a slight but not statistically significant decrease in LMMC birth prevalence. CONCLUSIONS: LMMC seems to be pathogenically distinct from myelomeningocele and more studies are needed to understand the embryologic mechanisms leading to this condition, and the environmental and genetic factors involved in its etiology.


Subject(s)
Folic Acid/administration & dosage , Food, Fortified , Meningomyelocele/epidemiology , Meningomyelocele/prevention & control , Canada , Female , Humans , Infant, Newborn , Male , Prevalence
4.
N Engl J Med ; 357(2): 135-42, 2007 Jul 12.
Article in English | MEDLINE | ID: mdl-17625125

ABSTRACT

BACKGROUND: In 1998, folic acid fortification of a large variety of cereal products became mandatory in Canada, a country where the prevalence of neural-tube defects was historically higher in the eastern provinces than in the western provinces. We assessed changes in the prevalence of neural-tube defects in Canada before and after food fortification with folic acid was implemented. METHODS: The study population included live births, stillbirths, and terminations of pregnancies because of fetal anomalies among women residing in seven Canadian provinces from 1993 to 2002. On the basis of published results of testing of red-cell folate levels, the study period was divided into prefortification, partial-fortification, and full-fortification periods. We evaluated the relationship between baseline rates of neural-tube defects in each province and the magnitude of the decrease after fortification was implemented. RESULTS: A total of 2446 subjects with neural-tube defects were recorded among 1.9 million births. The prevalence of neural-tube defects decreased from 1.58 per 1000 births before fortification to 0.86 per 1000 births during the full-fortification period, a 46% reduction (95% confidence interval, 40 to 51). The magnitude of the decrease was proportional to the prefortification baseline rate in each province, and geographical differences almost disappeared after fortification began. The observed reduction in rate was greater for spina bifida (a decrease of 53%) than for anencephaly and encephalocele (decreases of 38% and 31%, respectively). CONCLUSIONS: Food fortification with folic acid was associated with a significant reduction in the rate of neural-tube defects in Canada. The decrease was greatest in areas in which the baseline rate was high.


Subject(s)
Folic Acid/administration & dosage , Food, Fortified , Neural Tube Defects/epidemiology , Neural Tube Defects/prevention & control , Vitamin B Complex/administration & dosage , Canada/epidemiology , Humans , Infant, Newborn , Prevalence
5.
Cerebrovasc Dis ; 23(4): 304-8, 2007.
Article in English | MEDLINE | ID: mdl-17199089

ABSTRACT

BACKGROUND AND PURPOSE: Though the proportion of elderly stroke patients is increasing, patients >80 years are often excluded from clinical stroke trials. We reviewed the management of older patients presenting with acute ischemic stroke (AIS) and assessed the safety and efficacy of recombinant tissue plasminogen activator (rtPA) administration in a community-based setting. METHODS: A retrospective review of patients >80 years (n = 341) admitted to a community stroke center with AIS were compared to their younger counterparts (n = 690) using the stroke center database from April 2003 to December 2005. Parameters that were measured included admission and discharge NIH Stroke Scale (NIHSS), rate of thrombolytic treatment, the frequency and etiology of thrombolytic exclusion criteria and complications from rtPA for the different aged populations. Additional data were collected for Barthel Index at 12 months. RESULTS: A total of 166 patients underwent thrombolysis. Older patients were not delayed in reaching the hospital within 3 h of stroke onset (182/690, 26%, in the <80 cohort vs. 98/341, 29%, in the > or = 80 cohort). Although the overall rates of tPA use were similar in both the young and aged cohort, older patients were less likely to be treated with rtPA because of reasons not listed as exclusion criteria (17% in the <80 cohort vs. 32% in the > or = 80 cohort). The older group did not have an excess risk of intracranial hemorrhage following rtPA infusion despite equivalent NIHSS on admission (13.5 in the <80 cohort vs. 12.4 in the > or = 80 cohort). Both groups showed improvement in NIHSS following thrombolytic treatment with a drop of 7.7 points in the younger age group and 5.6 points in the older group. Elderly patients treated with rtPA had a comparable 12-month modified Barthel Index score to younger cohorts. CONCLUSIONS: Early treatment with rtPA in patients >80 years appears to be both safe and efficacious. Treated patients showed improvements both acutely (a decrease in NIHSS at 72 h) and chronically, as shown by a sustained improvement in the Barthel Index. A large number of elderly patients were excluded from rtPA treatment despite arriving within the time frame of treatment for reasons not considered as traditional exclusion criteria. Older patients with AIS can be treated safely with thrombolytic therapy in a community setting. This therapy should not be withheld on the basis of age.


Subject(s)
Fibrinolytic Agents/therapeutic use , Patient Selection , Stroke/drug therapy , Thrombolytic Therapy/statistics & numerical data , Tissue Plasminogen Activator/therapeutic use , Acute Disease , Age Factors , Aged , Aged, 80 and over , Brain Ischemia/complications , Cohort Studies , Community Health Centers/statistics & numerical data , Connecticut/epidemiology , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Middle Aged , Practice Guidelines as Topic , Recombinant Proteins/therapeutic use , Retrospective Studies , Severity of Illness Index , Stroke/epidemiology , Stroke/etiology , Thrombolytic Therapy/adverse effects , Time Factors , Tissue Plasminogen Activator/adverse effects , Transportation of Patients/statistics & numerical data , Treatment Outcome
6.
Proc Nutr Soc ; 62(2): 413-20, 2003 May.
Article in English | MEDLINE | ID: mdl-14506889

ABSTRACT

For many nutrients, a systematic determination of the effects of high intakes over extended periods of time has not been conducted. Governments and scientific bodies have just begun to establish the methodology for, and to conduct, nutrient risk assessments for setting 'tolerable upper levels of intake' (UL) for nutrients. Nutrient risk assessment provides the framework for using available information to evaluate the safety of nutrients when added to foods or when consumed as supplements, in order to minimize the risks from over-consumption. When intakes are inadequate, food fortification may be the appropriate choice for some nutrients, while in other situations, when requirements are markedly higher for some population subgroups than for the general population, supplements may be the most appropriate intervention. The present paper will present some examples of how to use the UL along with food consumption data to assess the appropriateness of food fortification v. supplementation strategies and to assess their impact on nutrient intakes of the population. The important steps to be followed when evaluating which approach is best are: (a) establishing need, i.e. assessing the gap between current and desired intakes; (b) assessing safety, i.e. consider the margin of safety between requirement and UL as well as the severity and reversibility of the adverse effect that was used to establish the UL; (c) estimating exposure through statistical modelling, in which population-based estimates of intakes before and after the intervention are compared; (d) monitoring the impact of the intervention to ensure that the desired benefits are achieved and that excessive intakes are minimized. This approach can optimize the public health benefits of food fortification or supplement use while minimizing the risks due to excessive intakes.


Subject(s)
Consumer Product Safety , Micronutrients/administration & dosage , Micronutrients/adverse effects , Dietary Supplements , Dose-Response Relationship, Drug , Food, Fortified , Humans , Micronutrients/deficiency , Needs Assessment , No-Observed-Adverse-Effect Level , Nutrition Assessment , Nutrition Policy , Risk Assessment
7.
J Nutr ; 133(7): 2232-8, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12840185

ABSTRACT

Fortification with calcium to increase dietary intakes of this mineral is currently under evaluation in Canada. To model the potential dietary consequences of food fortification, data from a large national survey of Canadians (n = 1543) were used. Food fortification scenarios were based on reference amounts for labeling requirements. Consumption of milk, cheese and other dairy products was associated with high calcium intakes, and there was a low prevalence of inadequacy in men < 50 y old; however, other age-sex groups had lower intakes. The aim of the fortification modeling was to determine which scenario would most effectively reduce the proportion of the population with low intakes of calcium while minimizing the proportion of individuals who exceeded the tolerable upper intake level (UL). Given the correlation between energy and calcium (r = 0.60, P < 0.01), it appeared that any fortification scenario sufficient to increase the mean intake for women to near the adequate intake led to 6-7% of the men having calcium intakes above the UL. The results suggest that fortification of widely consumed foods is not a realistic way to address the issue of low calcium intakes and illustrate the need for concern about the growing use of fortification practices.


Subject(s)
Calcium/administration & dosage , Food Supply , Food, Fortified , Adolescent , Adult , Aged , Canada , Humans , Middle Aged , Nutrition Policy , Nutrition Surveys
8.
Birth Defects Res A Clin Mol Teratol ; 67(11): 919-23, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14745929

ABSTRACT

BACKGROUND: In Canada, the first recommendations on the use of folic acid (FA) supplements by women planning a pregnancy or capable of becoming pregnant were issued in 1993. In 1998, fortification of flour with FA became mandatory. The objective of this study was to assess the impact of these measures on the prevalence of neural tube defects (NTDs) in the province of Quebec. METHODS: The study population included stillbirths, live births, and elective terminations for fetal malformations that were reported in 1992-2000 for women residing in the province of Quebec. NTD cases were identified from stillbirth certificates and hospital discharge summaries. RESULTS: There was a marked decrease in the total NTD rate after 1997. The average NTD rate was 1.89 per 1000 total births during the period of 1992-1997, and 1.28 per 1000 in 1998-2000, a 32% reduction (p < 0.001). CONCLUSIONS: Fortification of flour, which began in early 1997 and gradually became widespread, is a very plausible explanation for the timing, shape, and magnitude of the decrease in NTD prevalence observed in Quebec and other Canadian provinces. An increase in FA supplement use may have played only a minor role. Birth Defects Research (Part A) 67:000-000, 2003.


Subject(s)
Neural Tube Defects/epidemiology , Dietary Supplements , Female , Folic Acid/therapeutic use , Food, Fortified , Humans , Male , Pregnancy , Pregnancy Outcome , Prevalence , Quebec , Time Factors , Vitamins
SELECTION OF CITATIONS
SEARCH DETAIL